CS
SVA

Credit Suisse’s Sinovac Biotech, Ltd SVA Stock Holding History

Credit Suisse’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-656
Closed -$1K – 4265
2022
Q3 		$1K Hold
656
– – ﹤0.01% 4009
2022
Q2 		$1K Buy
+656
New +$1K ﹤0.01% 3873
2018
Q1 		– Sell
-20,700
Closed -$163K – 4286
2017
Q4 		$163K Sell
20,700
-4,039
-16% -$30.2K ﹤0.01% 3783
2017
Q3 		$174K Hold
24,739
– – ﹤0.01% 3971
2017
Q2 		$167K Hold
24,739
– – ﹤0.01% 3655
2017
Q1 		$142K Sell
24,739
-199
-0.8% -$1.15K ﹤0.01% 3666
2016
Q4 		$147K Sell
24,938
-64,490
-72% -$388K ﹤0.01% 3885
2016
Q3 		$527K Buy
89,428
+29,085
+48% +$171K ﹤0.01% 3391
2016
Q2 		$358K Buy
+60,343
New +$370K ﹤0.01% 3608
2015
Q3 		– Sell
-48,551
Closed -$255K – 4783
2015
Q2 		$255K Buy
48,551
+8,095
+20% +$42.8K ﹤0.01% 4096
2015
Q1 		$201K Buy
40,456
+20,530
+103% +$101K ﹤0.01% 4087
2014
Q4 		$104K Buy
19,926
+9,170
+85% +$46.8K ﹤0.01% 4428
2014
Q3 		$51K Sell
10,756
-4,162
-28% -$22.3K ﹤0.01% 4358
2014
Q2 		$85K Sell
14,918
-33,326
-69% -$202K ﹤0.01% 4561
2014
Q1 		$347K Buy
+48,244
New +$319K ﹤0.01% 3985
2013
Q4 		– Sell
-25,961
Closed -$156K – 4877
2013
Q3 		$156K Buy
+25,961
New +$124K ﹤0.01% 4035

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Credit Suisse's SVA Position: Q4 2022 in Review

Credit Suisse sold out of Sinovac Biotech, Ltd (SVA) in Q4 2022, closing a stake of 656 shares — an estimated $1K sold.

Credit Suisse first reported a position in SVA in Q3 2013 and held it in 16 quarters. The position peaked at $527K in Q3 2016. 9 funds tracked by Wall St. Rank hold SVA as of Q4 2022.

  • Credit Suisse reported no remaining Sinovac Biotech, Ltd position as of Q4 2022 after selling out during the quarter.
  • Credit Suisse sold 656 Sinovac Biotech, Ltd shares in Q4 2022, an estimated $1K.
  • Credit Suisse first reported a position in Sinovac Biotech, Ltd in Q3 2013 and held it in 16 quarters.
  • Credit Suisse's Sinovac Biotech, Ltd position peaked at $527K in Q3 2016.
  • 9 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.